1. Home
  2. WDC vs VRTX Comparison

WDC vs VRTX Comparison

Compare WDC & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Digital Corporation

WDC

Western Digital Corporation

N/A

Current Price

$447.87

Market Cap

151.1B

Sector

Technology

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$515.64

Market Cap

123.4B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
WDC
VRTX
Founded
1970
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
151.1B
123.4B
IPO Year
2000
2006

Fundamental Metrics

Financial Performance
Metric
WDC
VRTX
Price
$447.87
$515.64
Analyst Decision
Buy
Buy
Analyst Count
22
29
Target Price
$281.77
$539.69
AVG Volume (30 Days)
5.7M
945.9K
Earning Date
04-30-2026
05-04-2026
Dividend Yield
0.12%
N/A
EPS Growth
374.22
836.54
EPS
24.28
8.33
Revenue
$12,919,000,000.00
$2,488,652,000.00
Revenue This Year
$32.24
$10.79
Revenue Next Year
$26.55
$10.47
P/E Ratio
$19.91
$62.56
Revenue Growth
35.70
46.20
52 Week Low
$99.72
$374.17
52 Week High
$799.87
$560.25

Technical Indicators

Market Signals
Indicator
WDC
VRTX
Relative Strength Index (RSI) 47.69 44.26
Support Level $422.73 $425.34
Resistance Level $479.85 $533.67
Average True Range (ATR) 23.06 10.22
MACD 4.45 -5.20
Stochastic Oscillator 60.52 1.34

Price Performance

Historical Comparison
WDC
VRTX

About WDC Western Digital Corporation

Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: